Rocket Lab Sold Off. It's Still Priced Like a Sure Thing.

Rocket Lab just reported the best quarter in its history, and the stock is down roughly 58% from its high. That gap — record results, falling shares — is exactly where a "millionaire maker" story begins. The honest reading runs the other direction. Rocket Lab is a real company doing extraordinary things, and that is precisely why its price is the problem. At a market value near $38 billion on roughly $770 million of trailing sales — about 50x revenue, with free cash flow still deeply negative — the market has already paid for the dream the headlines invite you into. The millionaire-maker upside, in other words, is already in the price.

This is not a knock on the business. It is an answer to the valuation question that framing conveniently skips.

The best quarter in company history

Overstate what the company itself did, and you'd struggle. Second-quarter revenue came in at $234 million, up 62% year over year — a record. Quarterly backlog reached $2.36 billion, up 137%. Rocket Lab sits on roughly $2.1 billion in cash after raising capital and buying its way to a fuller stack. Alongside SpaceX, it is one of only two companies that has built an end-to-end space business: its own rockets, its own satellites, its own components. In the second quarter it closed acquisitions of Mynaric and Motivand struck an $8 billion deal for Iridium Communications. The ambition is real, and the execution so far has been real.

The report also shows why this encore isn't free. Rocket Lab lost $49 million in the quarter, used $134 million in operating cash over the first half, and burned roughly $371 million in free cash flow over the trailing year, against a GAAP gross margin near 36%. This is a company scaling impressively that still does not generate cash. The profit math rests on things that have not happened yet.

What multiplying the money requires

Here is the calculation no headline shows. A 10x gain for a new buyer means Rocket Lab's enterprise value rising from roughly $36 billion to something near $360 billion. Even holding a generous 20–25x sales multiple — far above what the broad market pays — that demands on the order of $15 billion of annual revenue, roughly twenty times today's run-rate, sustained for a decade with no multiple compression along the way.

That is the burden a 10x imposes on someone arriving at around $64 a share. The millionaire-talk is not wrong that this franchise could grow for years; it is wrong about who is left to be paid. Look at the twelve-month range — the stock touched $37.57 on the low end and $151 on the high. The people who made the eye-catching gains bought low in that window, before the market re-rated the story. The investor walking in after the fall is buying close to the destination, not at the departure gate.

The rocket that carries the multiple

The one catalyst capable of resetting the math — Neutron, the medium-lift rocket that would finally give Rocket Lab a reusable, Falcon-9-class vehicle — is also the piece most exposed. The company still targets delivering Neutron to the pad in the fourth quarter of 2026, but it will not commit to a first-flight date, and the window is "narrowing." A first-stage tank rupture during a January pressure test already pushed the debut back. Analysts and the company alike now leave room for the inaugural flight to slide into 2027.

The structural moat here is genuine, but the load-bearing proof is still on the ground. Rocket Lab has not cracked under the stress that moved the price — that test is simply not finished. When a multiple this rich rests on a not-yet-flown rocket, a delay or a failure doesn't just push revenue out; it crushes the multiple that the whole story depends on.

And the chart is not offering a contrarian entry. The shares trade below both the 50- and 200-day averages, are down about 16% over the past month, and have made no bottoming pattern. This is a falling price at a full valuation, not selling exhaustion underneath an intact, cheapened story.

Where the contrarian call lands

So let me be plain. The market is not wrong to have cooled on this stock. Quality clears the bar — Rocket Lab's franchise is broadening, its backlog is enormous, and its moat is not cracked. But the valuation-versus-growth test fails for a new buyer, and the piece of the business that would justify the multiple is unproven. The burden of proof sits with the bulls, and the totality of the evidence does not carry it for somebody paying fifty times sales.

That does not make Rocket Lab a sell for a holder, and it does not make it a buy for a watcher. It makes it a stock the "millionaire maker" label got to first — which is precisely why the easy money in it has likely already been made. A genuinely favorable risk/reward shows up only if the price compresses meaningfully or Neutron actually flies and revenue grows into that multiple. I would rather wait for one of those than be the last hand handed the ticket at the top of the story.